Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 May 2017
At a glance
- Drugs Ipilimumab (Primary) ; Paclitaxel (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 08 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2019.
- 08 May 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 27 Apr 2016 Status changed from recruiting to active, no longer recruiting.